Purpose To research the short-term safety of antidiuretic hormone in elderly

Purpose To research the short-term safety of antidiuretic hormone in elderly patients with nocturnal polyuria focus on hyponatremia and others electrolytes disturbances and to assess short-term effects on nocturnal urine output and number of nocturnal voids. were analyzed. Desmopressin treatment did not significantly change serum and urine electrolytes include soduim concentration in elderly patients comparied with adult patients. Serum sodium concentration below normal range was recorded in 2 patients in elderly group but no serious adverse events occurred and recovered without sequelae. The mean number of nocturnal voids Golvatinib decresed (54% reduction) and nocturnal urine output decreased (57% reduction) after using desmopressin. Conclusions Desmopressin was well tolerated and effective in elderly patients with nocturnal polyuria without clinically significant PSACH hyponatremia. Keywords: Desmopressin Nocturia Elderly Hyponatremia INTRODUCTION Nocturia is usually a common cause of sleep disturbance in elderly people and several studies have reported that its frequency increases as the patient ages [1-3]. It had generally been accepted that bladder and prostate diseases induce adult nocturia but recently the excessive production of urine has been found to be the major cause of nocturia. Various factors such as nocturnal polyuria nocturnal detrusor overactivity reduction of functional bladder capacity and also abnormalities of the lower urinary tract have also been found to function as single or combined etiologic factors [4-6]. Normally the secretion of antidiuretic hormone increases during the night and nocturnal urine output is reduced to minimize urine-induced awakening. A reduction of antidiuretic hormone secretion seems the major factor in the nocturia caused by nocturnal polyuria [7 8 With aging the secretion of antidiuretic hormone during the night declines to maintain a similar level during the day and night and this lack of difference becomes the major cause of adult nocturia [8]. Changes in the Golvatinib level of antidiuretic hormone are the theoretical basis for the usage of desmopressin which is an analogue of arginine vasopressin an antidiuretic hormone secreted from the posterior lobe of the hypophysis. An incresing number of reports indicate that administration of desmopressin to patients with nocturia seems to improve their symptoms [9]. However several studies have also reported that headache vomiting dizziness heart failure and hyponatremia often appear [10]. Hyponatremia in particular not only seems to occur more often in the elderly but can also be fatal in this population; therefore special caution is needed. Awareness of nocturia caused by nocturnal polyuria has been increasing Golvatinib in Korea and therefore the clinical use of desmopressin in adult nocturia patients is increasing. Only a few studies however have reported on the effects and safety of its administration. Therefore although its effects are recognized we are still fearful of the possible side effects. Appropriately we aimed to study the effects and also the incidence of adverse effects with desmopressin treatment. MATERIALS AND METHODS From June 2005 to August 2006 voiding diary information was Golvatinib collected from outpatients who frequented the urology department in our hospital with complaints of nocturia. Among these patients 34 adults aged 29-71 years experiencing nighttime urination of more Golvatinib than 2 times per night and also more than 33% of urine volume/day were enrolled. At the first visit information around the patient’s medical history and voiding diary was collected and physical examinations with liver and renal function assessments were performed. Serum electrolytes urine electrolytes and urine Golvatinib osmolality were also measured to exclude patients showing abnormal antidiuretic hormone levels as the result of chlorpropamide clofibrate or carbamazepine medication or those with heart failure renal failure or urinary tract infection. Drug safety was analyzed by comparing the results of serum electrolytes renal function assessments urine electrolytes and changes in urine osmolality on the 3rd 7 and 14th days after the start of medication. Other health problems compared with the previous point of administration were also investigated at the.